Merck's Keytruda (pembrolizumab) has hit the mark in the late-stage NRG-GY018 trial, with a combination of the drug plus chemotherapy improving progression-free survival (PFS) versus chemo alone ...
To act as the responsible entity for a range of public offer ethically managed investment schemes and to act as the Trustee of the Australian Ethical Retail Superannuation Fund (Super Fund).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback